Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.23.01540 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Nuh N Rahbari und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Ulm University hospital, Ulm, Germany. Hauptthemen laut MEDLINE: Colonic Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Chemotherapy is established as primary treatment in patients with stage IV colorectal cancer and unresectable metastases. Data from nonrandomized clinical trials have fueled persistent uncertainty if primary tumor resection (PTR) before chemotherapy prolongs survival. We investigated the prognostic value of PTR in patients with newly diagnosed stage IV colon cancer who were not amenable to curative treatment. PATIENTS AND METHODS Patients enrolled in the multicenter, randomized SYNCHRONOUS and CCRe-IV trials were included in the analysis. Patients with colon cancer with synchronous unresectable metastases were randomly assigned at 100 sites in Austria, Germany, and Spain to undergo PTR or up-front chemotherapy (No PTR group). The chemotherapy regimen was left at discretion of the local team. Patients with tumor-related symptoms, inability to tolerate surgery and/or systemic chemotherapy, and history of another cancer were excluded. The primary end point was overall survival (OS), and the analyses were performed with intention-to-treat. RESULTS A total of 393 patients were randomly assigned to undergo PTR (n = 187) or no PTR (n = 206) between November 2011 and March 2017. Chemotherapy was not administered to 6.4% in the No PTR group and 24.1% in the PTR group. The median follow-up time was 36.7 months (95% CI, 36.6 to 37.3). The median OS was 16.7 months (95% CI, 13.2 to 19.2) in the PTR group and 18.6 months (95% CI, 16.2 to 22.3) in the No PTR group ( P = .191). Comparable OS between the study groups was further confirmed on multivariate analysis (hazard ratio, 0.944 [95% CI, 0.738 to 1.209], P = .65) and across all subgroups. Patients with serious adverse events were more common in the No PTR group (10.2% v 18.0%; P = .027). CONCLUSION Among patients with colon cancer and synchronous unresectable metastases, PTR before systemic chemotherapy was not associated with prolonged OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Surgery, Ulm University hospital, Ulm, Germany.
- Department of General and Digestive Surgery-Colorectal Unit, Bellvitge University Hospital, University of Barcelona and IDIBELL, Barcelona, Spain.
- Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany.
- The Study Center of the German Society of Surgery (SDGC), University of Heidelberg, Heidelberg, Germany.
- Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
- Coordination Centre for Clinical Trials (KKS), University Hospital Heidelberg, Heidelberg, Germany.
ORCID-Profile: Nuh N Rahbari, Ricardo Frago, Monica Serrano, Florian Sommer, Axel Dignass, Claus Bolling, Gunnar Folprecht
Zitieren
APA
Rahbari, N. N., Biondo, S., Frago, R., Feißt, M., Kreisler, E., Rossion, I., Serrano, M., Jäger, D., Lehmann, M., Sommer, F., Dignass, A., Bolling, C., Vogel, I., Bork, U., Büchler, M. W., Folprecht, G., Kieser, M., Lordick, F., Weitz, J., & SYNCHRONOUS and CCRe-IV Trial Groups (2024). Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01540
Vancouver
Rahbari NN, Biondo S, Frago R, Feißt M, Kreisler E, Rossion I, et al. Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01540
BibTeX
@article{Rahbari2024,
author = {Rahbari, Nuh N and Biondo, Sebastiano and Frago, Ricardo and Feißt, Manuel and Kreisler, Esther and Rossion, Inga and Serrano, Monica and Jäger, Dirk and Lehmann, Monika and Sommer, Florian and Dignass, Axel and Bolling, Claus and Vogel, Ilka and Bork, Ulrich and Büchler, Markus W and Folprecht, Gunnar and Kieser, Meinhard and Lordick, Florian and Weitz, Jürgen and SYNCHRONOUS and CCRe-IV Trial Groups, SYNCHRONOUS and CCRe-IV Trial Groups},
title = {Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.23.01540}
}
EUVIMED